MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14737167.2021.1933948

Медицинская библиотека · Expert review of pharmacoeconomics & outcomes research · 2021

Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain.

Formiga Francesc, García-Pavía Pablo, Martín Sánchez Francisco Javier, Navarro-Ruiz Andrés, Rubio-Terrés Carlos, Peral Carmen, Tarilonte Patricia, López-Ibáñez de Aldecoa Alejandra, Rubio-Rodríguez Darío

СтатьяПеревод пока не подготовлен

Аннотация

Objective

To estimate the health and economic impact of the reduction in mortality and cardiovascular hospitalizations, associated with correct diagnosis of cardiac transthyretin amyloidosis (ATTR-CM), from the Spanish National Health System (NHS) perspective.

Methods

A costs and effects analysis were performed (probabilistic Markov model) with time horizons between 1 and 15 years, comparing the correct diagnosis of ATTR-CM versus the non-diagnosis. Transition probabilities were obtained from the ATTR-ACT study (placebo arm) and from the literature. Costs and healthcare resources were obtained from Spanish sources (€ 2019) and from a panel of Spanish clinical experts.

Results

After 1, 5, 10 and 15 years, the diagnosis of ATTR-CM would generate a gain of 0.031 (95%CI 0.025; 0.038); 0.387 (95%CI 0.329; 0.435); 0.754 (95%CI 0.678; 0.781) and 0.944 (95%CI 0.905; 0.983) life years per patient, respectively, with savings of € 212 (95%CI € -632; 633), € 2,289 (95%CI € 2,250; 2,517), € 2,859 (95%CI € 2,584; 3,149) and € 2,906 (95%CI € 2,669; 3,450) per patient, respectively, versus the non-diagnosis.

Conclusions

Just by correctly diagnosing ATTR-CM, years of life would be gained, cardiovascular hospitalizations would be avoided, and savings would be generated for the NHS, compared to the non-diagnosis of the disease.

Для цитирования: Formiga Francesc, García-Pavía Pablo, Martín Sánchez Francisco Javier, Navarro-Ruiz Andrés, Rubio-Terrés Carlos, Peral Carmen, Tarilonte Patricia, López-Ibáñez de Aldecoa Alejandra, Rubio-Rodríguez Darío. Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain.. Expert review of pharmacoeconomics & outcomes research. 2021. DOI: 10.1080/14737167.2021.1933948.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.